Overview

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks. This study will also assess the safety/efficacy of long-term treatment (52 weeks).
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Insulin
Insulin, Globin Zinc
Ipragliflozin